Press Releases | Clarus Therapeutics, Inc

Skip to main navigation

Investor Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly & Annual Reports
IR Resources
- Email Alerts
- Contact IR

Press Releases

Year

Sep 22, 2021

Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

Sep 16, 2021

Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies

Sep 15, 2021

Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 09, 2021

Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies

Jul 15, 2021

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

May 25, 2021

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

May 25, 2021

Clarus Therapeutics Defeats Lipocine’s Patent Infringement Lawsuit on Summary Judgment

Apr 27, 2021

Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming a Publicly Listed Company to Address Unmet Needs of Men and Women Through Development of Androgen and Metabolic Therapies

Mar 20, 2021

Clarus Therapeutics Presents Positive Safety and Efficacy Data for Jatenzo® (testosterone undecanoate) Oral Capsules, CIII at ENDO 2021, the Endocrine Society's Annual Meeting

Feb 24, 2021

Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer

2021 Copyright

Search Investor Relations